OWEN MUMFORD LIMITED

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Consolidated group

Auditor

The MGroup Partnership

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The current economic conditions present increased risks for all businesses. In response to such conditions, the directors have carefully considered these risks, including an assessment of uncertainty on future trading projections for a period of at least 12 months from the date of signing the financial statements, and the extent to which they might affect the preparation of the financial statements on a going concern basis. The directors consider that the going concern basis is appropriate to the presentation of the financial statements.”

Group structure

1. OWEN MUMFORD LIMITED · parent
   1. Medicross Limited 100% · UK
   2. Owen Mumford GmbH 100% · Germany
   3. Owen Mumford USA, Inc. 100% · United States of America
   4. OM-Medical-Shop GmbH 50% · Germany
   5. Owen Mumford Sdn. Bhd. 100% · Malaysia

Significant events

• “One of the group's largest customers was forced to withdraw an emergency autoinjector from the market... sales of this autoinjector restarted in the financial year ending 30th September 2025.”
• “Restrictions driven by the COVID-19 pandemic ... impact on demand continued ... Orders from major customers were depressed ... Hospitals have maintained some restrictions... difficult for sales teams to meet clinicians.”
• “Sales to the group's largest customer were £0.8m down... customer's drug losing US patent cover in January 2023 and the launch of several biosimilar alternatives, market share remained high for the innovator drug.”
• “Pharmacy Benefit Manager (PBM) activity in North America led to pen needle sales reducing... Competitors have increasingly secured exclusive deals with PBMs, which has resulted in the group being blocked from certain key accounts and led to reduced sales.”
• “Development and equipment revenues were less than expected... pharmaceutical businesses less willing to invest in bespoke development, preferring platform drug delivery devices... group reacted by developing Aidaptus, Unisafe and an autoinjector for Unisafe.”
• “Sales of a disposable autoinjector, for treating Rheumatoid Arthritis, developed for a Japanese customer continue to show encouraging growth.”
• “Group's unique active safety pen needle, SafeControl, made a solid contribution with sales... continuing to grow strongly.”
• “Group continues to grow sales in France due mainly to a distribution agreement with a world leading partner.”
• “Extraordinary losses of £2.4m resulting from fixed assets written off in the year.”
• “Owen Mumford in collaboration with the Stevanato Group, ... continued to successfully promote the ground-breaking Aidaptus device ... Several contracts were secured during the year with Aidaptus.”
• “The business is developing a reusable autoinjector to complement and to work with Unisafe, the group's spring free passive safety syringe... investment in digital solutions as connected healthcare.”
• “Unifine SafeControl, an active safety pen needle developed by Owen Mumford, continued to be heavily promoted during the year.”
• “The group recognises the importance of sustainability and there is a clear strategic intention for the business to invest in sustainable offerings, including the development of new or improved sustainable healthcare solutions.”
• “The group is proactively seeking new distribution deals for medical devices in existing and adjacent spaces. Activities in blood collection have continued.”
• “Activities have also continued to expand the group's presence in the pelvic healthcare segment... products acquired at the end of the previous financial year... have been launched in Germany and Singapore and were launched in the UK at the beginning of the financial year ending 30th September 2025.”
• “The group was committed to capital expenditure of an estimated £6,350,525 in respect of plant and machinery at 30th September 2024.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

3

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  -12.5%

  £82,660,498 → £72,340,093

• Cash

  +34%

  £12,376,708 → £16,582,158

• Net assets

  -2.3%

  £87,578,710 → £85,593,323

• Employees

  -12.7%

  732 → 639

• Operating profit

  +63.2%

  -£3,192,272 → -£1,175,100

• Profit before tax

  +13.5%

  -£2,980,062 → -£2,576,596

• Wages

  -19.5%

  £30,008,107 → £24,162,522

Each % is (latest − prior) ÷ |prior| for the line item as filed. Periods don't have to be exactly 12 months apart — a long or short period (typical around incorporation or year-end changes) will distort the comparison. Lines a company doesn't report are omitted. About these numbers